文献速递主动脉疾病内脏/肾动脉与血管畸形

基于E-xtra设计平台的内分支复杂主动脉修复:一项全国多中心注册研究结果

Inner branched complex aortic repair outcomes from a national multicenter registry using the E-xtra design platform.
PubMed 文献 · J Vasc Surg · 2022-09-05

该研究纳入2016至2021年意大利三家中心连续接受E-xtra设计内分支腔内移植物治疗并至少重建一支内脏动脉的45例患者,评估早期结局。技术成功率为93.3%(42/45),30天临床成功率为93.3%(42/45),36个月总生存率和目标内脏血管通畅率分别为83.9%和95.9%。作者认为内分支技术似乎有前景,但尚需进一步研究确定其与开窗/分支腔内修复的可比性。

要点

  • 45例复杂主动脉病变患者接受E-xtra设计内分支腔内移植物治疗,技术成功率为93.3%(42/45)。
  • 30天临床成功率为93.3%(42/45),30天内无死亡及目标内脏血管血栓形成。
  • 36个月Kaplan-Meier估计总生存率为83.9%,目标内脏血管通畅率为95.9%。

核心结论

  • 内分支在复杂主动脉修复领域似乎是一项有前景的技术,适用性从II型胸腹主动脉瘤到肾下腔内移植物术后I型内漏修复。
  • 内分支腔内动脉瘤修复(iBEVAR)在目标血管通畅性和支架稳定性方面能否提供与开窗/分支腔内动脉瘤修复相当的结果尚未确定,因此需要进一步研究。

研究设计与样本

  • 研究为多中心意大利经验,连续纳入三家意大利中心接受E-xtra设计装置治疗的所有患者。
  • 共45例患者接受E-xtra设计装置治疗,通过内分支重建至少一支内脏血管;2016年至2021年期间。
  • 主要目标为评估iBEVAR后的技术和临床成功;次要终点为随访期间总生存率、主动脉相关死亡率、目标内脏血管(TVV)通畅率和免于目标血管不稳定的比例。

主要发现

  • 手术时平均年龄为71.1 ± 9.3岁,男性占77.8%。
  • 需要以内分支桥接的目标内脏动脉总数为159支;主动脉修复范围为胸腹主动脉者占91.1%。
  • 技术成功率为93.3%(42/45),所有失败均因最终血管造影时的I型内漏;每支TVV均按计划成功连接至移植物主体,无并发症。
  • 术后5例患者发生脊髓缺血,其中3例症状在出院后持续存在(6.7%);30天临床成功率为93.3%(42/45),30天内无死亡及无TVV血栓形成。
  • 平均随访时间为22.8 ± 14.2个月;36个月时Kaplan-Meier估计的总生存率为83.9%,TVV通畅率为95.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complex aortic pathology still represents an open issue in contemporary endovascular management, with continuous technological advancement being introduced in practice over time aiming to improve outcomes. Thus far, the dualism between the fenestrated and branched configuration for visceral artery revascularization is yet unsolved, with each approach having its own pros and cons. The inner branched technology for endovascular aneurysm repair (iBEVAR) aims to take the best out of both strategies, offering wide applicability and stable bridging stent sealing. The objective of this study was to evaluate the early outcomes obtained with a single manufacturer custom-made inner-branched endograft in a multicenter Italian experience. METHODS: All patients consecutively treated with E-xtra design devices in three Italian facilities were enrolled. Anatomic characteristics and perioperative data were analyzed. The main objective was to asses technical and clinical success after iBEVAR. Secondary end points were overall survival, aortic-related mortality, target visceral vessel (TVV) patency, and freedom from target vessel instability during follow-up. RESULTS: From 2016 to 2021, 45 patients were treated with an E-xtra design device revascularizing at least one visceral vessel through an inner branch. The mean age at the time of the procedure was 71.1 ± 9.3 years and 77.8% were males. The total number of target visceral arteries to be bridged with an inner branch was 159. The extent of aortic repair was thoracoabdominal in 91.1% of the cases. Technical success was achieved in 93.3% of the procedures (42/45) with all failures owing to a type I endoleak at final angiography. Each TVV was successfully connected to the graft's main body as planned without complications. Following their intervention, five patients developed spinal cord ischemia and in three of these cases symptoms persisted after discharge (6.7%). At 30 days clinical success was 93.3% (42/45). No death as well as no TVV thrombosis occurred within 30 days from the primary procedures. The mean follow-up was 22.8 ± 14.2 months. The Kaplan-Meier estimate of overall survival and TVV patency at 36 months were 83.9% and 95.9%, respectively. CONCLUSIONS: Inner branches seem to be a promising technology in the complex aortic repair landscape, with an applicability ranging from type II thoracoabdominal aneurysm to type I endoleak repair after infrarenal endografting. Whether iBEVAR could offer results comparable with those provided by fenestrated/branched endovascular aneurysm repair in terms of target vessel patency and stent stability is yet to be established and further studies are, therefore, needed.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Simonte G, Isernia G, Gatta E, et al. Inner branched complex aortic repair outcomes from a national multicenter registry using the E-xtra design platform. J Vasc Surg. 2022. PMID: 36070846. doi:10.1016/j.jvs.2022.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。